Dendrite's President to Retire.

BEDMINSTER, N.J. -- Dendrite International, Inc. (NASDAQ: DRTE) the leading provider of sales, marketing, clinical and compliance solutions for the global pharmaceutical industry, today announced the retirement of their President and Chief Operating Officer, Mr. Paul Zaffaroni. The Company has coordinated Mr. Zaffaroni's retirement plans with the appointment of his successor.

During his five years at Dendrite, Mr. Zaffaroni transformed Dendrite's ability to provide world class customer service, and oversaw a substantial increase in Dendrite's growth. He expanded the company's offerings to include Samples Management and Direct Marketing Support, and in doing so positioned Dendrite to meet the Pharmaceutical Industry's changing Sales and Marketing Support needs.

"Paul has created a company that's unrecognizable from the small business he joined in 2001. On behalf of our customers, employees and shareholders, I want to thank Paul for his guidance, drive and initiative, all of which were needed to create Dendrite into the business it is today," said John Bailye, Chairman and Chief Executive Officer. "He leaves the company ready for its next stage of expansion and growth."

Dendrite simultaneously announced the appointment of its new President and COO, Mr. Joseph Ripp. Mr. Zaffaroni will continue in his current position until November 1, 2005, after which he will remain an employee of the company during a mutually agreeable transition period.

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) provides diversified sales, marketing, clinical and compliance solutions to the global life sciences and pharmaceutical industry. With clients in more than 50 countries, including the world's top 20 pharmaceutical companies, Dendrite strives to be the first source for expert promotional and sales effectiveness solutions. For more information, please visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This document contains forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for our products; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; risks associated with foreign currency fluctuations as they affect our non-U.S. operations; increased competition; risks associated with our expanded international operations and our ability to adopt and respond successfully to the unique risks involved in our non-U.S. operations; risks associated with acquisitions; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships or acquisitions; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the Company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The Company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in expectations or assumptions or other changes affecting such forward-looking statements, even if such results or changes make it clear that any such projected results will not be achieved.